CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Galectin Therapeutics Inc. - GALT CFD

    1.8665
    2.1%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0370
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Galectin Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 1.9065
    Open* 1.8765
    1-Year Change* 16.55%
    Day's Range* 1.8665 - 1.9065
    52 wk Range 1.02-2.47
    Average Volume (10 days) 26.52K
    Average Volume (3 months) 1.20M
    Market Cap 104.87M
    P/E Ratio -100.00K
    Shares Outstanding 59.58M
    Revenue N/A
    EPS -0.67
    Dividend (Yield %) N/A
    Beta 1.33
    Next Earnings Date Nov 13, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Oct 2, 2023 1.9065 -0.0400 -2.05% 1.9465 1.9465 1.8265
    Sep 29, 2023 1.8965 0.0600 3.27% 1.8365 1.9065 1.8265
    Sep 28, 2023 1.8965 0.1300 7.36% 1.7665 1.8965 1.7665
    Sep 27, 2023 1.8065 -0.0100 -0.55% 1.8165 1.8265 1.7665
    Sep 26, 2023 1.7965 -0.0300 -1.64% 1.8265 1.8565 1.7765
    Sep 25, 2023 1.8365 -0.0200 -1.08% 1.8565 1.8665 1.7665
    Sep 22, 2023 1.7465 0.0300 1.75% 1.7165 1.7765 1.6665
    Sep 21, 2023 1.7665 0.0300 1.73% 1.7365 1.7765 1.6965
    Sep 20, 2023 1.7765 -0.0800 -4.31% 1.8565 1.9165 1.7465
    Sep 19, 2023 1.9165 0.0700 3.79% 1.8465 1.9365 1.8465
    Sep 18, 2023 1.9365 0.1600 9.01% 1.7765 1.9565 1.7765
    Sep 15, 2023 1.7565 -0.1400 -7.38% 1.8965 1.9065 1.7365
    Sep 14, 2023 1.9065 -0.0600 -3.05% 1.9665 1.9665 1.8765
    Sep 13, 2023 1.9065 0.0800 4.38% 1.8265 1.9365 1.7865
    Sep 12, 2023 1.7865 0.1400 8.50% 1.6465 1.8065 1.6465
    Sep 11, 2023 1.6665 0.0400 2.46% 1.6265 1.6765 1.6265
    Sep 8, 2023 1.7160 0.0100 0.59% 1.7060 1.7360 1.7060
    Sep 7, 2023 1.7360 0.1000 6.11% 1.6360 1.7460 1.6360
    Sep 6, 2023 1.6360 -0.0400 -2.39% 1.6760 1.6760 1.6260
    Sep 5, 2023 1.6960 -0.0500 -2.86% 1.7460 1.7560 1.6360

    Galectin Therapeutics Inc. Events

    Time (UTC) Country Event
    Monday, November 13, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Q3 2023 Galectin Therapeutics Inc Earnings Release
    Q3 2023 Galectin Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Friday, December 1, 2023

    Time (UTC)

    16:00

    Country

    US

    Event

    Galectin Therapeutics Inc Annual Shareholders Meeting
    Galectin Therapeutics Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 38.352 30.179 23.444 13.438 13.602
    Selling/General/Admin. Expenses, Total 6.615 6.361 5.468 5.971 7.131
    Research & Development 31.737 23.818 17.976 7.467 6.471
    Operating Income -38.352 -30.179 -23.444 -13.438 -13.602
    Interest Income (Expense), Net Non-Operating -0.424 -0.348 -0.021 0.144 -0.298
    Net Income Before Taxes -38.776 -30.527 -23.465 -13.294 -13.9
    Net Income After Taxes -38.776 -30.527 -23.465 -13.294 -13.9
    Net Income Before Extra. Items -38.776 -30.527 -23.465 -13.294 -13.9
    Net Income -38.776 -30.527 -23.465 -13.294 -13.9
    Total Adjustments to Net Income -0.097 -0.171 -0.137 -6.885 -1.147
    Income Available to Common Excl. Extra. Items -38.873 -30.698 -23.602 -20.179 -15.047
    Income Available to Common Incl. Extra. Items -38.873 -30.698 -23.602 -20.179 -15.047
    Diluted Net Income -38.873 -30.698 -23.602 -20.179 -15.047
    Diluted Weighted Average Shares 59.391 58.527 57.029 52.238 39.414
    Diluted EPS Excluding Extraordinary Items -0.65453 -0.52451 -0.41386 -0.38629 -0.38177
    Diluted Normalized EPS -0.65453 -0.52451 -0.41386 -0.38629 -0.38177
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 9.003 10.342 10.633 8.122 9.662
    Selling/General/Admin. Expenses, Total 1.632 1.543 1.626 1.524 1.588
    Research & Development 7.371 8.799 9.007 6.598 8.074
    Operating Income -9.003 -10.342 -10.633 -8.122 -9.662
    Interest Income (Expense), Net Non-Operating -0.111 -1.185 -0.001 -0.475 0.049
    Net Income Before Taxes -9.114 -11.527 -10.634 -8.597 -9.613
    Net Income After Taxes -9.114 -11.527 -10.634 -8.597 -9.613
    Net Income Before Extra. Items -9.114 -11.527 -10.634 -8.597 -9.613
    Net Income -9.114 -11.527 -10.634 -8.597 -9.613
    Total Adjustments to Net Income -0.063 0 -0.065 0.016 -0.064
    Income Available to Common Excl. Extra. Items -9.177 -11.527 -10.699 -8.581 -9.677
    Income Available to Common Incl. Extra. Items -9.177 -11.527 -10.699 -8.581 -9.677
    Diluted Net Income -9.177 -11.527 -10.699 -8.581 -9.677
    Diluted Weighted Average Shares 59.582 59.48 59.424 59.396 59.389
    Diluted EPS Excluding Extraordinary Items -0.15402 -0.1938 -0.18005 -0.14447 -0.16294
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.15402 -0.1938 -0.18005 -0.14447 -0.16294
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 20.552 41.82 29.465 48.209 8.832
    Cash and Short Term Investments 18.592 39.648 27.142 47.48 8.253
    Cash & Equivalents 18.592 39.648 27.142 47.48 8.253
    Prepaid Expenses 1.96 2.172 2.323 0.729 0.579
    Total Assets 21.285 41.827 29.6 48.467 9.006
    Property/Plant/Equipment, Total - Net 0.086 0.007 0.048 0.084 0
    Property/Plant/Equipment, Total - Gross 0.081 0.122 0.158 0.074
    Accumulated Depreciation, Total -0.074 -0.074 -0.074 -0.074
    Intangibles, Net 0
    Total Current Liabilities 13.012 9.033 5.399 2.82 2.108
    Accounts Payable 3.89 1.805 1.292 1.661 0.297
    Accrued Expenses 9.058 7.163 4.042 1.093 1.512
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.064 0.065 0.065 0.066 0.299
    Total Liabilities 53.479 39.211 5.407 2.872 2.108
    Total Long Term Debt 39.828 29.048 0 0 0
    Total Equity -32.194 2.616 24.193 45.595 6.898
    Redeemable Preferred Stock 2.233 2.25 2.25 2.26 2.26
    Preferred Stock - Non Redeemable, Net 6.682
    Common Stock 0.059 0.059 0.056 0.056 0.041
    Additional Paid-In Capital 275.081 271.001 261.883 259.673 194.13
    Retained Earnings (Accumulated Deficit) -309.567 -270.694 -239.996 -216.394 -196.215
    Total Liabilities & Shareholders’ Equity 21.285 41.827 29.6 48.467 9.006
    Total Common Shares Outstanding 59.426 59.3413 57.0771 56.8946 41.1909
    Total Preferred Shares Outstanding 1.26018 1.30268 1.30268 1.32768 6.83568
    Other Long Term Assets, Total 0.647 0.087 0.174 0.174
    Other Liabilities, Total 0.639 1.13 0.008 0.052
    Long Term Debt 39.828 29.048
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 19.552 20.552 17.121 25.785 33.507
    Cash and Short Term Investments 17.799 18.592 15.831 24.178 31.606
    Cash & Equivalents 17.799 18.592 15.831 24.178 31.606
    Prepaid Expenses 1.753 1.96 1.29 1.607 1.901
    Total Assets 20.225 21.285 17.914 25.886 33.615
    Property/Plant/Equipment, Total - Net 0.078 0.086 0.093 0.101 0.108
    Other Long Term Assets, Total 0.595 0.647 0.7
    Total Current Liabilities 11.533 13.012 9.588 10.892 9.535
    Accounts Payable 2.553 3.89 2.352 2.964 1.906
    Accrued Expenses 8.98 9.058 7.236 7.864 7.629
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0 0.064 0 0.064 0
    Total Liabilities 62.871 53.479 40.249 41.109 39.808
    Total Long Term Debt 49.941 39.828 29.734 29.504 29.275
    Other Liabilities, Total 1.397 0.639 0.927 0.713 0.998
    Total Equity -42.646 -32.194 -22.335 -15.223 -6.193
    Redeemable Preferred Stock 2.233 2.233 2.233 2.233 2.25
    Common Stock 0.059 0.059 0.059 0.059 0.059
    Additional Paid-In Capital 276.156 275.081 274.241 272.772 272.108
    Retained Earnings (Accumulated Deficit) -321.094 -309.567 -298.868 -290.287 -280.61
    Total Liabilities & Shareholders’ Equity 20.225 21.285 17.914 25.886 33.615
    Total Common Shares Outstanding 59.5822 59.426 59.426 59.3958 59.3885
    Total Preferred Shares Outstanding 1.26018 1.26018 1.26018 1.26018 1.30268
    Long Term Debt 49.941 39.828 29.734 29.504 29.275
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -38.776 -30.527 -23.465 -13.294 -13.9
    Cash From Operating Activities -31.056 -24.308 -20.601 -10.848 -10.179
    Cash From Operating Activities 0
    Non-Cash Items 2.752 2.468 1.922 1.805 4.793
    Changes in Working Capital 4.968 3.751 0.942 0.641 -1.072
    Cash From Investing Activities 0 0 0
    Capital Expenditures 0
    Cash From Financing Activities 10 36.814 0.263 50.075 15.379
    Issuance (Retirement) of Stock, Net 0 6.814 0.263 50.469 15.379
    Net Change in Cash -21.056 12.506 -20.338 39.227 5.2
    Total Cash Dividends Paid 0 -0.394
    Other Investing Cash Flow Items, Total 0 0
    Issuance (Retirement) of Debt, Net 10 30
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -11.527 -38.776 -28.142 -19.545 -9.932
    Cash From Operating Activities -10.793 -31.056 -23.817 -15.47 -8.042
    Non-Cash Items 1.607 2.752 2.206 1.176 0.719
    Changes in Working Capital -0.873 4.968 2.119 2.899 1.171
    Cash From Financing Activities 10 10 0 0 0
    Issuance (Retirement) of Stock, Net 0 0 0 0
    Net Change in Cash -0.793 -21.056 -23.817 -15.47 -8.042
    Issuance (Retirement) of Debt, Net 10 10 0 0
    Cash From Investing Activities 0
    Other Investing Cash Flow Items, Total 0

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Galectin Therapeutics Inc. Company profile

    About Galectin Therapeutics Inc

    Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).

    Equity composition

    Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.

    Industry: Biotechnology & Medical Research (NEC)

    Suite 240
    4960 Peachtree Industrial Boulevard
    NORCROSS
    GEORGIA 30071
    US

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    Oil - Crude

    88.95 Price
    +1.340% 1D Chg, %
    Long position overnight fee 0.0501%
    Short position overnight fee -0.0720%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    XRP/USD

    0.52 Price
    -1.500% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    BTC/USD

    27,470.60 Price
    -1.570% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Gold

    1,827.73 Price
    -0.060% 1D Chg, %
    Long position overnight fee -0.0194%
    Short position overnight fee 0.0112%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading